Labor Market Overview - The U.S. labor market showed signs of cooling in November with nonfarm payrolls rising by 64,000, which is only modestly above expectations and weak by historical standards, while the unemployment rate unexpectedly climbed to 4.6% [1] Stock Market Performance - The Dow Jones Industrial Average fell 0.6% to 48,114.26, while the S&P 500 dropped 0.2% to 6,800.26; the Nasdaq rose 0.2% to 23,111.46 [1] Tilray Brands Inc. - Tilray Brands Inc. saw a significant increase of 27.54%, closing at $13.94, after trading between an intraday low of $10.50 and a high of $14.55; the stock remains below its 52-week peak of $23.20 but above its 52-week low of $3.51 [2][3] - The rally was fueled by speculation regarding potential U.S. cannabis reclassification following comments from President Donald Trump and positive remarks from CEO Irwin Simon [3] Pfizer Inc. - Pfizer's stock fell by 3.48% to finish at $25.53, with intraday trading between a low of $24.92 and a high of $26.51; shares are below their 52-week high of $27.69 but above the 52-week low of $20.92 [4][5] - The decline followed a cautious long-term outlook, with a new 2026 forecast indicating slower growth due to fading COVID-19 revenues and potential losses of exclusivity, despite cost-cutting measures and a focused R&D pipeline [5] Netflix Inc. - Netflix Inc. increased by 0.85% to close at $94.57, trading between an intraday low of $93.32 and a high of $94.93; the stock remains below its 52-week high of $134.12 but above its 52-week low of $82.11 [6] - The rise in stock price was attributed to a new podcast partnership with iHeartMedia, which aims to broaden Netflix's audio and content ecosystem [6] Lennar Corporation - Lennar Corporation's stock slipped by 1.80% to settle at $117.57, with intraday trading between a high of $120.82 and a low of $116.70; shares are below their 52-week high of $153.48 but above the 52-week low of $98.42 [7][8] - The company reported fourth-quarter revenue of $9.37 billion, beating estimates, but adjusted earnings of $2.03 per share missed expectations; home sales revenue fell by 7% to $8.9 billion [8] - New orders rose by 18% year over year to 20,018 homes, and deliveries increased by 4% to 23,034, although affordability pressures and weak consumer confidence impacted results [8] Tesla Inc. - Tesla Inc. climbed by 3.07% to close at $489.88, reaching an intraday high of $491.50 and a low of $465.83; shares are at a new 52-week high of $491.50, significantly above the 52-week low of $214.25 [9][10] - The increase was driven by heightened enthusiasm around autonomy, robotics, and software, with a surge in interest in its robotaxi program and Optimus humanoid robots, alongside bullish commentary from analysts [10]

Core Viewpoint - The U.S. President is anticipated to sign an executive order to expedite the reclassification of cannabis, which could significantly impact the cannabis industry and its regulatory landscape [1] Group 1: Executive Order Impact - The executive order is expected to fast-track the reclassification process of cannabis, potentially leading to changes in its legal status and regulatory framework [1] - This move may open up new opportunities for investment and growth within the cannabis sector, as it could facilitate easier access to banking and financial services [1] Group 2: Industry Implications - The reclassification could lead to increased legitimacy for cannabis businesses, attracting more investors and enhancing market confidence [1] - A shift in cannabis classification may also influence state-level regulations and encourage further legalization efforts across the country [1]

A shift in federal marijuana policy could be coming.Shares of Trulieve Cannabis Corp (TCNNF +14.13%) soared on Tuesday, finishing the day up 14.1%. The jump comes as the S&P 500 lost 0.3% and the Nasdaq Composite gained 0.2%.The cannabis stock is surging after President Donald Trump confirmed a report that his administration is exploring marijuana reclassification -- a shift that could reshape the cannabis industry and have an immediate impact on Trulieve's business. OTC : TCNNFTrulieve CannabisToday's Chan ...

Tilray (TLRY) shares soared about 30% today after President Donald Trump said he’s “strongly” considering an executive order that will reclassify cannabis as a Schedule III drug. The expected mandate will also authorize a pilot program that will enable seniors to access cannabis products under Medicare coverage, according to media reports on Tuesday. More News from Barchart Following today’s surge, Tilray stock is up more than 100% versus its recent low set on Dec. 4. www.barchart.com What Cannabis R ...

Industry Overview - Cannabis stocks experienced a downturn for a second consecutive day despite President Trump's consideration of an executive order to loosen marijuana regulations [1] - The Amplify Seymour Cannabis ETF (CNBS) saw a significant drop of nearly 7% after a previous surge of over 50% on Friday, indicating profit-taking by investors [2] Regulatory Changes - President Trump indicated that he is "considering" an executive order to reclassify marijuana, which could lead to increased research opportunities [2] - Reports suggest that the reclassification would move marijuana from a Schedule I substance to a Schedule III drug, aligning it with less regulated substances like steroids and Tylenol with codeine [3] Market Sentiment - The cannabis sector experienced a rally on Friday, marking the Amplify Seymour fund's best day on record and putting it on track to end a four-year losing streak [3] - Industry insiders express optimism about the potential for regulatory changes to attract banks and large investors to the cannabis sector, with Tilray's CEO noting increased optimism [4] - Despite the overall positive sentiment, major cannabis producers like Tilray and Canopy Growth saw declines of 10% and 4.6%, respectively, while retailer SNDL dropped over 13% on Monday [4]

Group 1: Market Reaction and Regulatory Changes - Canadian cannabis stocks, including Tilray (TLRY), surged following reports that President Donald Trump could sign an executive order reclassifying marijuana from a Schedule I drug to Schedule III, which would allow cannabis companies to deduct business expenses and improve access to banking services [1] - Tilray's stock jumped 44% on Friday, reflecting strong market sentiment following the news [2] Group 2: Financial Performance - In fiscal Q1 of 2026, Tilray reported record revenue of $210 million, a 5% year-over-year increase, driven by gains in both domestic and international markets [4] - Sales for adult-use cannabis in Canada rose 12%, while international revenue increased by 10% year-over-year [5] - Tilray achieved a net income of $1.5 million in Q1, a significant improvement from a loss of $34.7 million in the same period last year [5] Group 3: Operational Developments - The beverage segment remained flat as management rationalized its SKUs under Project 420, which has generated $25 million in annual savings [6] - Tilray's craft beer portfolio performed well, with Shock Top emerging as a top-selling brand in the Southeast, where dollar sales rose 49% year-over-year [7] Group 4: Balance Sheet and Financial Health - Tilray strengthened its balance sheet by reducing outstanding debt by $7.7 million, ending with $265 million in cash [8] - The company raised $22.5 million through its at-the-market equity program, improving its net debt to adjusted EBITDA ratio to 0.07x, providing flexibility for future growth investments [8]

Marijuana stocks surged Friday after reports that Trump could sign an executive order reclassifying cannabis. ...

Big news in the cannabis world and the markets are lighting up. I'm Brandon Gomez at CNBC headquarters and cannabis stocks today are surging. Why.Well, sources are telling me President Donald Trump could sign an executive order as soon as Monday to reclassify cannabis at the federal level. Right now, cannabis is a schedule one drug, same category as heroin. The executive order would drop it to schedule three in the same bucket as steroids and Tylenol with coding.Now, this is big. It means lower taxes, acces ...

Core Insights - The U.S. marijuana industry has faced stagnation due to federal inaction on reclassification or decriminalization, with cannabis classified as a Schedule I drug, limiting research and access to banking services [1][2] - President Trump's potential executive order to reclassify marijuana as a Schedule III substance could significantly impact the industry, attracting institutional investors and improving banking access [3][5][8] Industry Overview - The U.S. marijuana market is valued at approximately $32 billion, with state-level sales exceeding $30 billion annually, yet investors remain cautious due to the Schedule I classification [3][8] - Reclassification could double industry growth rates to 20% annually, although full effects may take 12 to 18 months due to rulemaking delays [8] Company Impacts Tilray Brands (TLRY) - Tilray could benefit from eased U.S. entry and the ability to import medical products interstate, with fiscal 2025 revenue reaching $821 million, up 4% [9] - The end of the 280E tax penalty could boost after-tax profits by 40% to 70%, allowing for expansion [10] Canopy Growth (CGC) - Canopy Growth, already profitable in Canadian medical sales, could see significant savings of $50 million to $70 million annually from eased tax burdens, funding U.S. market entry [12][13] - The company aims for a 30% increase in EBITDA by 2027, leveraging its global presence [13] Aurora Cannabis (ACB) - Aurora Cannabis stands to gain from reclassification, which would ease research and distribution of its pharmaceutical-grade products [14] - The company reported a fiscal Q2 2026 net income of $81 million Canadian, with potential for 15% revenue growth [15] Legislative Context - Trump's executive order aims to bypass administrative hearings and expedite marijuana's shift to Schedule III, which recognizes moderate abuse potential and accepted medical value [5][10] - While reclassification does not fully legalize marijuana, it could unlock significant changes in the industry landscape [7][10] Market Sentiment - Following news of the potential executive order, cannabis stocks like Tilray, Canopy Growth, and Aurora Cannabis saw double-digit percentage gains, indicating renewed investor interest [4][6]

Core Viewpoint - Cannabis stocks, including Tillray and Aurora, are experiencing significant gains due to reports that the president plans to reclassify marijuana to a less dangerous category, potentially moving it from Schedule I to Schedule III, similar to Tylenol with codeine [1][2] Group 1: Reclassification Process - The president is reportedly drafting an executive order to advise the DOJ and DEA to proceed with the reclassification, which could be issued as soon as Monday [2] - Following the executive order, the DOJ and DEA will publish a final rule, which will then enter a 30-day waiting period for any challenges, indicating potential delays due to opposition [4] Group 2: Industry Perspectives - Tillray's CEO, Irwin Simon, expresses optimism about the reclassification, believing that there will be significant changes by the end of the year, marking a departure from previous false starts [3] - A cannabis lawyer suggests that this reclassification could signal the beginning of a new era in public health policy, although it is viewed as a partial victory with ongoing legalization and regulatory challenges ahead [5] Group 3: Implications of Reclassification - The reclassification is not equivalent to legalization but is expected to facilitate medical research on cannabis, which could lead to broader acceptance and potential future legalization at the federal level [6][8] - The industry hopes that increased medical use will eventually pave the way for more recreational cannabis products, especially in light of recent legislative actions like the hemp ban [8]